ECSP23065907A - Uso de luvadaxistat para el tratamiento de deterioro cognitivo - Google Patents

Uso de luvadaxistat para el tratamiento de deterioro cognitivo

Info

Publication number
ECSP23065907A
ECSP23065907A ECSENADI202365907A ECDI202365907A ECSP23065907A EC SP23065907 A ECSP23065907 A EC SP23065907A EC SENADI202365907 A ECSENADI202365907 A EC SENADI202365907A EC DI202365907 A ECDI202365907 A EC DI202365907A EC SP23065907 A ECSP23065907 A EC SP23065907A
Authority
EC
Ecuador
Prior art keywords
luvadaxistat
treatment
cognitive impairment
compound
administering
Prior art date
Application number
ECSENADI202365907A
Other languages
English (en)
Inventor
Thomas A Macek
Maura L Furey
Jagannatham Naga Venkatesha Murthy Pathi
Satjit Singh Brar
Nicholas Demartinis
Brian Harel
Jaskaran B Singh
Tingting Ge
Patricio O'donnell
Eduardo Dunayevich
Original Assignee
Takeda Pharmaceuticals Co
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co, Neurocrine Biosciences Inc filed Critical Takeda Pharmaceuticals Co
Publication of ECSP23065907A publication Critical patent/ECSP23065907A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos para tratar al menos un síntoma cognitivo, por ejemplo, al menos un síntoma cognitivo asociado con esquizofrenia, que comprende administrar al menos un compuesto elegido del Compuesto (I) y sales farmacéuticamente aceptables del mismo. También se describen métodos para incrementar los niveles de D-serina, plasticidad sináptica, y/o potenciación a largo plazo que comprende administrar al menos un compuesto elegido del Compuesto (I) y sales farmacéuticamente aceptables del mismo.
ECSENADI202365907A 2021-03-01 2023-08-31 Uso de luvadaxistat para el tratamiento de deterioro cognitivo ECSP23065907A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163200327P 2021-03-01 2021-03-01
US202163229945P 2021-08-05 2021-08-05
US202163264747P 2021-12-01 2021-12-01
US202163265628P 2021-12-17 2021-12-17

Publications (1)

Publication Number Publication Date
ECSP23065907A true ECSP23065907A (es) 2023-09-29

Family

ID=80780614

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202365907A ECSP23065907A (es) 2021-03-01 2023-08-31 Uso de luvadaxistat para el tratamiento de deterioro cognitivo

Country Status (16)

Country Link
US (1) US20240408086A1 (es)
EP (1) EP4301367A1 (es)
JP (1) JP2024508860A (es)
KR (1) KR20230154217A (es)
AU (1) AU2022228417A1 (es)
CA (1) CA3209781A1 (es)
CL (1) CL2023002558A1 (es)
CO (1) CO2023011625A2 (es)
DO (1) DOP2023000174A (es)
EC (1) ECSP23065907A (es)
IL (1) IL305210A (es)
JO (1) JOP20230198A1 (es)
MX (1) MX2023010140A (es)
PE (1) PE20232048A1 (es)
TW (1) TW202302109A (es)
WO (1) WO2022187127A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201403944D0 (en) 2014-03-06 2014-04-23 Takeda Pharmaceutical New use

Also Published As

Publication number Publication date
JP2024508860A (ja) 2024-02-28
IL305210A (en) 2023-10-01
CL2023002558A1 (es) 2024-03-22
AU2022228417A1 (en) 2023-10-26
MX2023010140A (es) 2023-10-12
TW202302109A (zh) 2023-01-16
KR20230154217A (ko) 2023-11-07
WO2022187127A1 (en) 2022-09-09
EP4301367A1 (en) 2024-01-10
CA3209781A1 (en) 2022-09-09
JOP20230198A1 (ar) 2023-08-28
US20240408086A1 (en) 2024-12-12
DOP2023000174A (es) 2024-01-31
PE20232048A1 (es) 2023-12-27
CO2023011625A2 (es) 2023-12-11

Similar Documents

Publication Publication Date Title
CL2021001228A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CO2025011012A2 (es) Agonistas heterocíclicos de glp-1
CO2022001814A2 (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
MX2021003170A (es) Moduladores de la expresion de pnpla3.
CO2022015630A2 (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
AR112101A1 (es) Tinostamustina para usar en el tratamiento de la leucemia prolinfocítica de celulas t (t-pll).
CL2021000329A1 (es) Compuestos útiles en terapia del vih
CL2020001851A1 (es) Moduladores de la expresión dnm2
CO2021012559A2 (es) Compuestos macrocíclicos como agonistas de sting
MX2022007626A (es) Combinaciones.
CO2018001237A2 (es) Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos
BR112022012280A2 (pt) Combinações
BR112022019114A2 (pt) Dosagem qd de compostos peptídicos agonistas do receptor de gip e usos dos mesmos
ECSP23065907A (es) Uso de luvadaxistat para el tratamiento de deterioro cognitivo
MX390507B (es) Compuestos de amida y su uso.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
MX2022011475A (es) Azd1656 para el uso en el tratamiento de neumonitis y/o la miocarditis causadas por un coronavirus.
CL2020002147A1 (es) 3ß-(4-metoxibenciloxi)pregn-5-en-20-ona para su uso en el tratamiento de los trastornos relacionados con los cannabinoides.
MX2021011007A (es) Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco.
CO2023015732A2 (es) Moduladores de trex1
MX2023012742A (es) Uso de inhibidores de mmp para el tratamiento del sindrome de dificultad respiratoria aguda.
CL2025001435A1 (es) Compuestos inhibidores de ddr1 para tratar cáncer.
CL2025000601A1 (es) Compuestos de bloqueo de canal de sodio, derivados de los mismos y metodos para su uso.
UY38255A (es) Técnica de tensado del espacio uretro-vaginal para el tratamiento de la incontinencia de orina de esfuerzo, e instrumentos para su práctica